Hubert montagner

First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide - dexamethasone followed by lenalidomide for . Lenalidomide (Revlimid) is authorised in combination with dexamethasone for treatment of multiple myeloma in patients who have received at . Lenalidomide and dexamethasone has been a standard of care in transplant- ineligible patients with newly diagnosed multiple myeloma. Lenalidomide can reduce the risk of progression from smoldering multiple myeloma (SMM) to multiple myeloma (MM), according to a phase 2/3 . Reason for Update: Changes to SPC and NICE TA 171. PHARMAC is pleased to announce the approval of a proposal for azacitidine ( Vidaza), lenalidomide (Revlimid) and thalidomide (Thalomid). Lenalidomide is an immunomodulatory agent used in the treatment of multiple myeloma, myelodysplastic syndrome, (MDS) and relapsed or .